COMPOSITION | |
---|---|
Propranolol | 40MG |
Flunarizine | 10MG |
Propranolol Flunarizine
MIGOVIB PLUS
SPECIFICATION | |
---|---|
FORM | CAPSULE |
PACKING | 10×10 |
PACKING TYPE | BLISTER |
MRP | – |
DESCRIPTION
A widely used non-cardioselective beta-adrenergic antagonist. Propranolol is used in the treatment or prevention of many disorders including acute myocardial infarction, arrhythmias, angina pectoris, hypertension, hypertensive emergencies, hyperthyroidism, migraine, pheochromocytoma, menopause, and anxiety. [PubChem]
Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
SIDE EFFECTS
Symptoms of overdose include bradycardia, cardiac failure, hypotension, and brochospasm. LD50=565 mg/kg (orally in mice).
Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.
INDICATION
For the prophylaxis of migraine.
“-Flunarizine should be used with care in patients with depression or those being prescribed other agents, such as phenothiazines, concurrently, which may cause extrapyramidal side-effects.
-Acute overdosage has been reported and the observed symptoms were sedation, agitation and tachycardia.
-Treatment of acute overdosage consists of charcoal administration, induction of emesis or gastric lavage, and supportive measures. No specific antidote is known.”